Is Research Square Worth It? Good Visibility, Real Tradeoffs

Research Square is best understood as a preprint and publication-support platform, not as a reviewer.

Three specific facts from its support and product pages matter most:

1. Research Square's support center says In Review is a free preprint service for manuscripts submitted to participating journals.
2. The same support page says In Review was developed in partnership with Springer Nature and currently serves 1000+ participating journals.
3. Research Square's support content says that once a preprint is posted, it cannot be removed, receives a DOI, and becomes a citable part of the scientific record with a lasting indexed presence.

That combination is what makes the platform valuable and risky at the same time.

1. It can accelerate visibility

For some papers, speed matters. A lot.

If the work is time-sensitive, competitive, or useful to the community before journal publication is complete, a preprint can create immediate upside:

• earlier discovery
• earlier citations
• earlier feedback
• a public timestamp on the work

Research Square is built to make that easier, especially when In Review is available through the submission workflow of a participating journal.

2. In Review lowers the friction of posting

This is one of the platform's strongest operational advantages. Authors at participating journals can choose a route that ties preprint posting to submission rather than making it a separate process.

The support documentation also says In Review provides a peer review timeline, which is helpful for transparency and for co-authors or readers who want to understand where the manuscript sits in the process.

That makes Research Square feel less like an isolated repository and more like a workflow layer attached to formal publishing.

3. Indexing makes the visibility real

Research Square's support content says its preprints are indexed through Crossref, Europe PMC, Google Scholar, Researcher, ResearchGate, and Meta, with PubMed Central indexing a limited subset.

That matters because discoverability is not abstract. A preprint is only strategically useful if people can actually find it.

Research Square clears that bar.

The most important sentence in Research Square's support content is not about reach. It is about permanence.

Once the preprint is posted:

• it cannot simply be removed
• it receives a DOI
• it becomes citable
• indexing creates a lasting digital footprint

This is not just a legalistic footnote. It should drive the decision.

If you are proud of the manuscript and want it public, this is a strength.

If you are uncertain whether the draft is ready to be associated with your name permanently, this is a real risk.

That is why Research Square is not a neutral "why not?" tool. It is a publishing choice.

This is where the wrong expectations create bad decisions.

Research Square does not tell you:

• whether the claims are strong enough for the target journal
• whether the figures will survive reviewer scrutiny
• whether the citations are thin or out of date
• whether the paper is heading toward desk rejection

It is not a manuscript review layer.

So if the manuscript is still scientifically uncertain, the logical first step is not preprint posting. It is Manusights AI Review, or a deeper pre-submission review route, before you decide whether public exposure is a good idea.

That is why the two products should not be confused.

Research Square changes how widely the paper is seen.

Manusights changes how confidently you should send it.

Research Square is worth it for authors who:

• want early visibility before final journal publication
• value a DOI and discoverability
• are comfortable with preprints being part of the public record
• are submitting to journals that support In Review
• see strategic advantage in showing progress or staking timing

This can be especially compelling in:

• fast-moving biomedical areas
• competitive methods work
• interdisciplinary work that benefits from early exposure
• collaborations where public proof of progress matters

In those cases, the platform can do exactly what authors want it to do.

It is less worth it if:

• you are still unsure the manuscript is strong enough
• you are worried about public scrutiny of an early version
• the work is vulnerable to being misunderstood outside the journal context
• your co-author group is not aligned on preprint exposure

This is not fearmongering. It is just responsible sequencing.

If the manuscript may still need major scientific changes, public permanence becomes a harder sell.

Many authors worry that posting through In Review might influence journal decisions. Research Square's support content explicitly says opting into In Review does not influence decisions made by the journal or the likelihood of acceptance.

That is an important reassurance.

But it does not erase the strategic tradeoff. The journal may not care, while you still care deeply about whether an early version of the paper is public and citable.

Those are separate concerns, and authors should keep them separate.

Research Square is worth it for the right kind of author: someone who wants earlier visibility, accepts permanence, and is using the platform as a dissemination choice rather than as a substitute for review.

It is not a manuscript quality tool, and people get into trouble when they treat it like one.

So the honest verdict is:

Yes, Research Square can be worth it.

No, it should not be your first move if you are still unsure the paper is ready.

Make the manuscript stronger first with Manusights AI Review. Then decide whether public visibility is an advantage you actually want.

1. Alternatives to Research Square
2. Pre-submission review complete guide